AI English summary of an SEC filing — figures as filed
Elevance Health ELVThe company said the increase in benefit expense in Q3 2024 was driven by Medicaid rates being inadequate to cover medical cost trends. It said the rise in the benefit expense ratio reflected the shift in the mix of its Medicaid membership base related to eligibility redeterminations.
Key points
AI summaryThe company said the increase in benefit expense in Q3 2024 was driven by Medicaid rates being inadequate to cover medical cost trends. It said the rise in the benefit expense ratio reflected the shift in the mix of its Medicaid membership base related to eligibility redeterminations.
The company said Health Benefits operating revenue rose in Q3 2024 mainly due to premium rate increases in all lines of business, partially offset by Medicaid membership attrition. It said the decline in operating gain was driven by Medicaid rates being inadequate to cover medical cost trends.
The company said operating expense decreased in Q3 2024, partially offset by the accrual for the Provider Settlement Agreement associated with the BCBSA Litigation. It also cited this accrual as a factor in the increase in the operating loss in the Corporate & Other segment.
The company said that as of September 30, 2024, there were no outstanding amounts under the 5-Year Facility, which has a maximum limit of $4,000, or under its commercial paper program, which has a limit of $4,000. Short-term borrowings from the FHLBs were $360, and as of December 31, 2023 they were $225.
Key figures
Quarter ended September 30, 2024
- Revenue
- $45.1B
- Operating income
- $1.4B
- Net income
- $1.0B
- EPS
- $4.36
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Medicaid Rates and Benefit Expense Ratio
The company said the increase in benefit expense in Q3 2024 was driven by Medicaid rates being inadequate to cover medical cost trends. It said the rise in the benefit expense ratio reflected the shift in the mix of its Medicaid membership base related to eligibility redeterminations.
Source · Based on the MD&A text of the filing
Health Benefits Operating Gain Changes
The company said Health Benefits operating revenue rose in Q3 2024 mainly due to premium rate increases in all lines of business, partially offset by Medicaid membership attrition. It said the decline in operating gain was driven by Medicaid rates being inadequate to cover medical cost trends.
Source · Based on the MD&A text of the filing
Provider Settlement Agreement Related to BCBSA Litigation
The company said operating expense decreased in Q3 2024, partially offset by the accrual for the Provider Settlement Agreement associated with the BCBSA Litigation. It also cited this accrual as a factor in the increase in the operating loss in the Corporate & Other segment.
Source · Based on the MD&A text of the filing
Credit Facilities and Liquidity
The company said that as of September 30, 2024, there were no outstanding amounts under the 5-Year Facility, which has a maximum limit of $4,000, or under its commercial paper program, which has a limit of $4,000. Short-term borrowings from the FHLBs were $360, and as of December 31, 2023 they were $225.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…